Nick Karos thrilled by listing of UI on Frankfurt stock exchange
UI CEO made a statement "Our capital markets and investor relations strategy includes the FSE listing. We recently began trading on the OTCQB Exchange in the United States, and curiosity in the UI story is growing in Europe, particularly Germany. With a mushrooming market and interest in psychedelic medications, Germany has a reputation for innovation and leadership."
Daytrader
$HEM announced incorporation of an entirely owned subsidiary
The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem cell technology will be acquired by PreCerv from Hemostemix.
Universal Ibogaine Inc. CEO’s ecstatic to work with Blue Digital
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
$HMTXF going up in flash on the OTC
$HMTXF today marked quite an impressive opening in the otc market and is currently trading with a steady pace at $0.1960 with a notable spike
Hemostemix hires new financial advisor to the family
Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has joined hemostemix as a special financial advisor.
$IBO announced a vital addition of clinical trials directorJulie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.
$IBOGF CEO Thoughts on H.C Wainwright.It gives UI great pleasure to announce that Nick Karos, CEO, will speak at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond. On June 27, 2022, a hybrid online and offline event will take place. "H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
$IBO’S CEO comments on the H.C Wainwright
"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
GBPJPY SMALL TF SETUPGbp Jpy is making a pullback to support and demand orderblock,marked in the purple box. A hold of this area can send GBPJPY to supply zone marked on charts. This setup has a good R/R and multiple confluences that it will play out. Please note: Do not risk more then 2% of capital on this trade.
Blue digital media to highlight $IBO narrativeThe UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
$HEM recoups legal guardianship of its lost intellectual The company has legally retrieved all intellectual data related to stage 2 clinical trial data, along with all previous data from Hemostemix Israel and the randomized table needed to evaluate ACP-01 clinical trial data in North America and South Africa.